1
EXHIBIT 10.25
INTELLECTUAL PROPERTY SECURITY AGREEMENT
This Intellectual Property Security Agreement (the "Security Agreement")
is made and entered into as of this 13th day of August, 1996, by and among
PerImmune Holdings, Inc., whose address is 0000 Xxxxxxx Xxxxx, Xxxxxxxxx,
Xxxxxxxx 00000-0000 ("Holdings"), PerImmune, Inc. ("PerImmune"), Akzo Nobel
Pharma International, B.V., a corporation formed under the laws of the
Netherlands ("Pharma"), Organon Teknika Corporation ("OTC" together with
Pharma, the "Secured Parties") and Pharma, in its capacity as Collateral Agent
hereunder ("Collateral Agent").
RECITAL
WHEREAS, pursuant to that certain Promissory Note (the "Purchase Price
Note") dated as of August 2, 1996, made by Holdings pursuant to Section 2.2 of
the Stock Purchase Agreement, dated as of July 1, 1996 (as amended, modified or
supplemented from time to time) (the "Stock Purchase Agreement"), Holdings has
promised to pay to OTC an amount equal to Nine Million Two Hundred Thirty-four
Thousand Nine Hundred Thirty-five Dollars ($9,234,935).
WHEREAS, pursuant to a certain credit agreement, dated as of August 2,
1996 (as amended, modified or supplemented from time to time) (the "Credit
Agreement") between PerImmune and OTC, OTC has agreed to make to or for the
account of PerImmune certain loans up to Three Million Six Hundred Thousand
Dollars ($3,600,000) as may be increased by One Million Eight Hundred Thousand
Dollars ($1,800,000) in accordance with such Credit Agreement, to be evidenced
by PerImmune's Secured Promissory Note (the "Secured Note").
WHEREAS, pursuant to a certain working capital facility, dated as of
August 2, 1996 (as amended, modified or supplemented from time to time) (the
"Working Capital Facility") between PerImmune and OTC, OTC has agreed to make
to or for the account of PerImmune certain loans up to Two Million Eight
Hundred Seventy-one Thousand Five Hundred Thirty-two Dollars ($2,871,532) to be
evidenced by PerImmune's Working Capital Secured Note (the "Working Capital
Note").
WHEREAS, pursuant to a certain intellectual property agreement by and
between Holdings and Pharma dated as of August 2, 1996 (the "Intellectual
Property Agreement") whereby, in consideration of the transfer to Holdings of
certain patents and patent applications and other intellectual property,
Holdings has agreed to make to Pharma certain future payments.
WHEREAS, the parties hereto intend that the respective obligations of
Holdings under the Purchase Price Note and under the Intellectual Property
Agreement, and of PerImmune under the Credit Agreement and the Working Capital
Facility shall be secured by a pledge of Holdings' right, title and interest
in the Collateral (as defined herein).
1
2
WHEREAS, the parties hereto intend that Pharma act as Collateral Agent for
the equal and ratable benefit of the Secured Parties.
AGREEMENT
Now therefore, in consideration of the above recitals and the agreement
hereinafter set forth, the parties hereto agree as follows:
1. Creation of Security Interest. In order to secure the payment and
performances of all Obligations, Holdings hereby grants to the Collateral
Agent, for the equal and ratable benefit of the Secured Parties, a security
interest in all of Holdings' right, title and interest in and to the collateral
described in Section 2 below (the "Collateral") in order to secure the payment
and performance of the respective obligations of PerImmune and Holdings to
Secured Parties described in Section 3 below.
2. Collateral.
(a) The Collateral under this Security Agreement shall mean (i)
those certain patents and patent applications set forth in Schedule A
attached hereto (including, without limitation, all divisions,
continuations, continuations-in-part, reissues, renewals or extensions
thereof) (the "Patents") and (ii) those certain trademarks set forth on
Schedule B attached hereto (including all goodwill of Holdings' business
connected with the use of, and symbolized by, any and all such trademarks)
(the "Trademarks").
(b) If, before the termination of this Agreement, Holdings shall
become entitled to the benefit of any patent or patent application for any
division, continuation, continuation-in-part, reissues, renewal or
extension of a Patent, the provisions of Section 1 shall automatically
apply thereto and Holdings shall give to the Collateral Agent prompt notice
thereof in writing. Holdings authorizes the Collateral Agent to modify this
Agreement by amending Schedule A to reflect the addition of such patents or
patent applications.
3. Secured Obligations of Debtor. The Collateral secures and shall
hereafter secure (i) the payment by PerImmune to OTC of all indebtedness now or
hereafter owed to OTC by PerImmune under the Credit Facility, the Secured Note,
the Working Capital Facility, the Working Capital Note and this Security
Agreement together with any interest thereon and extensions, modifications and
renewals thereof, and (ii) the payment of Holdings (a) to OTC of all
indebtedness owed to OTC under the Purchase Price Note, and (b) to Pharma of
all amounts due pursuant to Section 2.2(a)(i) and Section 2.2(b) of the
Intellectual Property Agreement prior to the termination of this Agreement and
(iii) performance by Holdings of all other obligations and the discharge of all
other liabilities to Secured Parties of every kind and character, direct or
indirect, absolute or contingent, due or to become due, now existing or
hereafter arising, joint, several and joint and several, created under this
Security Agreement (together, the "Obligations"). All payments and performance
shall be in
2
3
accordance with the terms under which said indebtedness, obligations and
liabilities were or are hereafter incurred or created.
4. The Collateral Agent. Pharma is hereby appointed as the
Collateral Agent to serve in such capacity until a successor is duly appointed.
The Collateral Agent hereby accepts such appointment and acknowledges that it
is acting in such capacity for the benefit of the Secured Parties.
5. Restrictions on Future Agreements. Holdings agrees that, except
as set forth in Section 8 hereof, until the Obligations shall have been
satisfied in full and this Agreement shall have been terminated, Holdings will
not, without the Collateral Agent's prior written consent, (a) enter into any
agreement that is inconsistent with Holdings' obligations under this Agreement
or (b) sell, pledge, license or assign its interest in any of the Collateral.
6. Defaults and Remedies
Holdings shall be in default under this Agreement upon the happening
of any of the following events:
(a) PerImmune fails to pay or perform any of the obligations
owed to OTC in accordance with the terms upon which such obligations were
incurred or created under the Secured Note or the Working Capital Note and such
failure continues thereafter for a period of thirty (30) days after such sum
becomes due and owing.
(b) Holdings fails to pay or perform any of the obligations
owed to OTC under the Purchase Price Note or to Pharma under Section 2.2(a)(i)
and Section 2.2(b) of the Intellectual Property Agreement in accordance with
the respective terms upon which such obligation was incurred or created and
such failure continues thereafter, in the case of the Purchase Price Note, for
a period of thirty (30) days after such sum becomes due and owing, and in the
case of payments under Section 2.2(a)(i) and Section 2.2(b) of the Intellectual
Property Agreement, for a period of thirty (30) days after written notice to
Holdings that such sums are due and owing.
(c) All or any portion of the Collateral is seized or levied by
writ of attachment, garnishment, execution or otherwise and such seizure or
levy is not released within fifteen (15) days thereof.
(d) PerImmune executes a general assignment for the benefit of
its credits, ceases to conduct its business in the ordinary course as it is now
conducted, convenes any meeting of its creditors, becomes insolvent, admits in
writing its insolvency or inability to pay its debts, or is unable to pay or is
generally not paying its debts as they become due.
(e) Holdings executes a general assignment for the benefit of
its creditors, ceases to conduct its business in the ordinary course as it is
now
3
4
conducted, convenes any meeting of its creditors, becomes insolvent, admits
in writing its insolvency or inability to pay its debts, or is unable to
pay or is generally not paying its debts as they become due.
(f) A receiver, trustee, custodian or agent is appointed to take
possession of all or any substantial portion of PerImmune's assets.
(g) A receiver, trustee, custodian or agent is appointed to take
possession of all or any portion of the Collateral or all or any
substantial portion of Holdings' assets.
(h) Any case or proceeding is voluntarily commenced by PerImmune
under any provision of the Federal Bankruptcy Code or any other federal or
state law relating to debtor rehabilitation, insolvency, bankruptcy,
liquidation or reorganization, or any such case or proceeding is
involuntarily commenced against PerImmune.
(i) Any case or proceeding is voluntarily commenced by Holdings
under any provision of the Federal Bankruptcy Code or any other federal or
state law relating to debtor rehabilitation, insolvency, bankruptcy,
liquidation or reorganization, or any such case or proceeding is
involuntarily commenced against Holdings.
Upon such default hereunder, Collateral Agent, acting for the benefit of the
Secured Parties, shall have the remedies of a secured party under the
applicable Uniform Commercial Code and as set forth in Section 10, PerImmune or
Holdings, as appropriate, shall reimburse the Collateral Agent for all
reasonable costs and reasonable attorney's fees incurred by Collateral Agent in
pursuing any remedies, which costs and fees are also Obligations secured
hereunder.
7. Use and Pledge of Pledged Collateral. Unless an event of default
shall have occurred, Collateral Agent, on behalf of Secured Parties, shall from
time to time execute and deliver, upon written request of Holdings, any and all
instruments, certificates or other documents, in the form so requested,
necessary or appropriate in the reasonable judgment of Holdings to enable
PerImmune to continue to exploit, license, use, enjoy and protect the
Collateral throughout the world provided such instrument, certificate or
document does not conflict with nor diminish the rights of the Collateral Agent
or the Secured Parties hereunder and provided that Holdings gives adequate
assurance that the proceeds of the proposed transaction will be applied toward
any payment obligations that will be due and owing to Pharma under the
Intellectual Property Agreement as a result of such transaction. The parties
hereto each acknowledges that this Agreement is intended for the benefit of the
Collateral Agent on behalf of the Secured Parties and to grant a security
interest in and lien upon the Collateral and that, notwithstanding the
provisions of Section 10 hereof, shall not constitute or create a present
assignment of the Collateral.
8. Transfer of Collateral. The parties hereto each recognize and
acknowledge the right of Holdings under the Intellectual Property Agreement to
transfer and
4
5
assign to PerImmune all of Holdings' rights, title and interest in the
Collateral, and the Collateral Agent and the Secured Parties agree to promptly
execute and deliver all further documents and instruments, and to take all
further actions that may be necessary or that Holdings or PerImmune may
request, in order to reflect or acknowledge such transfer. Upon consummation of
the transfer of the Collateral, PerImmune shall be bound by all terms of this
Agreement.
9. Termination of Agreement. This Security Agreement shall terminate
upon the earlier of (i) full and final payment and performance of all
indebtedness and obligations secured hereunder, and (ii) in the absence of a
default hereunder, two (2) years from the date of this Security Agreement
(provided that such term shall be extended for the length of any cure period if
an event has occurred which would constitute a default if not for the
additional time allowed for the cure period). At such time, Collateral Agent
shall promptly execute and deliver to Holdings all deeds, assignments and other
instruments (including termination statements on Form UCC-3 and documents
suitable for recordation in the United States Patent and Trademark Office, the
United States Copyright Office or similar domestic or foreign authority)
acknowledging the termination of this Agreement and the release of the security
interest in the Collateral created hereunder.
10. Conditional Assignment.
10.1 In order to induce the Secured Parties to provide funds and
credit as set forth above, Holdings has agreed to make the conditional
assignment described in this Section 10 to the Collateral Agent of the Patents
and the Trademarks to secure Holdings' and PerImmune's performance of their
Obligations pursuant to this Agreement.
10.2 Holdings hereby conditionally grants, assigns and conveys to the
Collateral Agent the entire right, title and interest in and to the Patents and
the Trademarks. The parties hereto acknowledge that the conditional assignment
pursuant to this Section 10.2 shall have no effect, and the Collateral Agent
shall have no ownership interest in the Patents and the Trademarks pursuant to
this Section 10.2, unless and until there shall have occurred an event of
default under Section 6 above. Upon termination of this Agreement pursuant to
Section 9 above, the conditional assignment pursuant to this Section 10.2 shall
be terminated, and thereafter shall not be given any effect. Upon the
occurrence of an event of default hereunder, any and all rights, residual,
inchoate, by license or of any kind, that Holdings may have in the Patents and
the Trademarks shall be deemed assigned to Collateral Agent, which shall then
have the entire right, title and interest in and to the Patents and the
Trademarks, free of any obligation to Holdings, by effect of this conditional
assignment.
10.3 If, before the Obligations shall have been satisfied in full,
Holdings shall become entitled to the benefit of any patent application or
patent for any reissue, division, continuation, renewal, extension, or
continuation-in-part of any Patent or any improvement on any Patent, the
provisions of Section 10.2 shall automatically apply thereto and Holdings shall
give to Collateral Agent prompt notice thereof in writing. Holdings
5
6
authorizes Collateral Agent to modify this Agreement by amending Schedule A to
include any such future patents and patent applications.
11. Miscellaneous Provisions
11.1 Notices. Notices, requests and other communications hereunder
shall be in writing and may be delivered personally or sent by telegram, telex
or first class mail to the parties addressed as follows:
To PerImmune:
PerImmune, Inc.
0000 Xxxxxxx Xxxxx
Xxxxxxxxx, XX 00000-0000
Attention: Xxxxxxx X. Xxxxx, Xx.
To Holdings:
PerImmune Holdings, Inc.
0000 Xxxxxxx Xxxxx
Xxxxxxxxx, XX 00000-0000
Attention: Xxxxxxx X. Xxxxx, Xx.
To Pharma:
Akzo Nobel Pharma International, B.V.
X.X. Xxx 00 0000 XX
Xxx, Xxx Xxxxxxxxxxx
Attn: General Counsel
To OTC:
Organon Teknika Corporation
000 Xxxx Xxxxxx
Xxxxxx, X.X. 00000
Attn: President
Such notices, requests and other communications sent as provided above shall be
effective when received by the addressee thereof, but if sent by registered or
certified mail, postage prepaid, shall be effective three (3) business days
after being deposited in the United States mail. The parties hereto may change
their addresses by giving notice thereof to the other parties hereto in
conformity with this section.
11.2 Headings. All headings have been inserted for convenience only
and shall not affect the meaning or interpretation of this Security Agreement
or any provision hereof.
6
7
11.3 Governing Law. This Security Agreement shall be construed in
accordance with and all disputes hereunder shall be governed by the laws of the
State of Maryland.
11.4 Binding Agreement. All rights of Secured Parties hereunder
shall inure to the benefit of each of its successors and assigns. PerImmune
shall not assign any of its interest under this Security Agreement without the
prior written consent of Secured Parties.
11.5 Definitions. All terms not defined herein shall have the
meaning set forth in the applicable Uniform Commercial Code, except where the
context otherwise requires.
11.6 Entire Agreement. This Security Agreement, the Credit
Agreement, the Working Capital Agreement, the Purchase Price Note, the Secured
Note and the Working Capital Note executed in connection herewith, are intended
by the parties as a final expression of their agreement and are intended as a
complete and exclusive statement of the terms and conditions thereof.
11.7 Severability. If any provision of this Security Agreement
should be found to be invalid or unenforceable, all of the other provisions
shall nonetheless remain in full force and effect to the maximum extent
permitted by law.
11.8 Jurisdiction. Pharma (including in its capacity as Collateral
Agent) hereby irrevocably submits for the benefit of PerImmune and Holdings to
the jurisdiction of the federal district courts located in the State of
Maryland in connection with any controversy, suit, action or proceeding which
may arise out of or in connection with this Security Agreement and the
transactions contemplated hereby. Pharma (including in its capacity as
Collateral Agent) hereby irrevocably waives any objection which it might now or
hereafter have to the courts referred to in the preceding sentence being
nominated as the forum to hear and determine any controversy, suit, action or
proceeding which may arise out of or in connection with this Security Agreement
and the transactions contemplated hereby, on the basis of improper venue,
inconvenient forum or otherwise, and agrees not to claim that any such court is
not a convenient or appropriate forum.
11.9 Agent for Service of Process.
(a) In connection with this Security Agreement and the
transactions contemplated hereby, Pharma (including in its capacity as
Collateral Agent) hereby agrees that the process by which any suit, action
or proceeding is begun in the federal district courts located in the State
of Maryland may be served on it by being delivered to Organon Teknika
Corporation, 000 Xxxx Xxxxxx, Xxxxxx, X.X. 00000, Attn: President, and
hereby irrevocably appoints such person as its agent for the service of
process in connection therewith. If the appointment of the person
mentioned in this Section 11.9 ceases to be effective, Pharma shall
immediately appoint a further person to accept service of process on its
behalf in Maryland and, failing such
7
8
appointment within five (5) days after notice thereof to Pharma, Holdings
or PerImmune shall be entitled to appoint such a person by notice to
Pharma. Pharma (including in its capacity as Collateral Agent) further
irrevocably consents to the service of process out of the aforementioned
courts in any such action or proceeding by the mailing of copies thereof
by registered or certified mail, postage prepaid, to Pharma, at the
address identified for it in Section 11.1, such service to become
effective ten (10) days after such mailing. Nothing contained herein shall
affect the right to serve process in any other manner permitted by law.
(b) The submission to the jurisdiction of the courts referred
to above shall not (and shall not be construed so as to) limit the right
of Holdings or PerImmune hereby to take proceedings against Pharma
(including in its capacity as Collateral Agent) with respect to this
Security Agreement and the transactions contemplated hereby in any other
court of competent jurisdiction nor shall the taking of proceedings in any
one or more jurisdictions preclude the taking of proceedings in any other
jurisdiction (whether concurrently or not) if and to the extent permitted
by applicable law.
Counterparts. This Security Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which shall
together constitute one and the same agreement.
8
9
IN WITNESS WHEREOF, the parties hereto have caused this Security
Agreement to be duly executed as of the day and year first above written.
PerImmune, Inc.
By [SIG]
---------------------------
Title
---------------------------
PerImmune Holdings, Inc.
By [SIG]
---------------------------
Title
---------------------------
Akzo Nobel Pharma International, B.V.
By [SIG]
---------------------------
Title
---------------------------
Organon Teknika Corporation
By [SIG]
---------------------------
Title
---------------------------
Akzo Nobel Pharma International, B.V.
as Collateral Agent
By [SIG]
---------------------------
Title
---------------------------
10
Schedule A
Intellectual Property Security Agreement
Patents and Patent Applications
Title Country Patent # Allowed App # Filed App #
Monoclonal Antibodies
Tumor specific monoclonal
antibodies US 4,828,991
Tumor associated
monoclonal antibodies
derived from human B-cell US 4,997,762
line 5,180,814
AT E71410
AU 589,351
635,511
BE 0151030
CA 473130
CH 0151030
DE P3585093
DK 408/85
EP 0151030
ES 539,987
FR 0151030
GB 0151030
GR 850,179
HU 209,519
IE 58,859
IL 74,156
91,045
IT 0151030
JP 2021518 269230/93
LU 0151030
NL 0151030
NZ 210,867
PT 79,894
SE 0151030
ZA 8,500,689
11
Schedule A
PATENTS AND PATENT APPLICATIONS
Title Country Patent # Allowed App# Filed App#
Tumor specific monoclonal antibodies US 5,106,738
Tumor associated monoclonal antibody 8IAV78 US 5,348,880
XX 000000
XX 0000000
EP 92913154.8
FI 935038
XX 000000/00
XX 93/703412
WO US92/04023
Tumor associated monoclonal antibodies US 5,474,755
Monoclonal Antibody 88BV59 US 08/341469
AU 651,261
CA 2083542
EP 92203827.8
FI 925638
HU 9203932
ID P-005142
IL 103258
XX 000000/00
XX 92/23925
NO 924803
NZ 245443
TW 81109353
ZA 92/8880
Monoclonal antibody 88BV59, sublones and
method of making US 08/192089
AU 17425/95
CA 2158572
EP 95909472.3
FI 954700
JP 520778/95
12
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
TITLE COUNTRY PATENT # ALLOWED APP# FILED APP #
----- ------- ----------- ------------ -----------
KR 95/704282
WO US95/01440
Tumor associated monoclonal US 5,495,002
antibody 000XX00
XX X-000000
WO EP95/00581
ZA 95/1113
In-vitro method for producing US 5,229,275
antigen specific human
monoclonal antibodies
AT E123,311
AU 647;112
BE 0,454,225
CA 2,041,213
CH 0,454,225
DE 69,110,084.5
sss
DK 0,454,225
EP 0,454,225
ES 0,454,225
FI 912,016
FR 0,454,225
GB 0,454,225
GR 3,017,162
IE 66,523
IT 0,454,225
XX 000000/00
XX 91/6661
NL 0,454,225
SE 0,454,225
ZA 91/2998
Imaging infectious foci with US 08/346,988
human IgM 16.88
13
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
TITLE COUNTRY PATENT # ALLOWED APP # FILED APP #
CHELATORS
Method for purifying chelator conjugated compounds US 5,244,816
AU 656,717
CA 2,069,303
DK 0488/92
EP 90915696.0
FI 921,579
IE 3585/90
XX 000000/00
XX 92/700833
NZ 235,618
PT 95574
WO US90/05772
ZA 90,8095
Chelating agents for attaching metal ions to proteins US 5,292,868 08/430657
5,488,126
AT E128035
AU 638,757
BE 0429644
CA 2,033,086
CH 0429644
DE 690225423
DK 0429644
EP 0429644 95200465.3
ES 0429644
FI 910,329
FR 0429644
GB 0429644
IE 1867/90
14
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
TITLE COUNTRY PATENT # ALLOWED APP # FILED APP #
IT 0429644
XX 000000/00
XX 91/700100
NL 0429644
SE 0429644
WO US90/02910
ZA 90/4047
Technetium/99M labelling of proteins US 5,317,091
AU 658,403
CA 2104943
EP 92907824.4
FI 933760
XX 000000/00
XX 93/702561
WO US92/01577
Chelator IDAC-2 and methods for purifying US 08/278721
chelator conjugated compounds 08/442856
WO US95/09285
New Polyaminocarboxylate chelators US 95/00068
WO US95/00068
Pre-Targeting
Site specific in vivo activation of US 5,433,955 07/300999
therapeutic drugs 08/382469
AT E123414
AU 648,015
BE 0454783
CA 2025899
CH 0454783
DE 69019959.7
DK 0454783
15
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
Title Country Patent # Allowed App # Filed App #
EP 0454783
ES 0454783
FI 913,511
FR 0454783
GE 0454783
IT 0454783
XX 000000/00
XX 90/702129
LU 0454783
NL 0454783
NO 912,864
SE 0454783
WO 90/00503
In Vivo Binding Pair Pretargeting US 08/140186 08/452938
08/461267
AU 663,582
CA 2,107,558
EP 93906276.6
FI 934,857
ID P-005991
XX 000000/00
XX 93/703311
WO US93/01858
ZA 93/3035
High yield preparation of dimeric US 08/397464
to decameric chitin xxxxxxxxx
XX 000000
WO US96/02705
16
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
Title Country Patent # Allowed App # Filed App #
Polymer affinity systems in the US 08/471264
delivery of cytotoxic materials
and other compounds to the site
of disease
Immunotherapy
Active specific immunotherapy US 5,484,596 08/540298
CTAA 28A32, the antigen recognized US 08/041529
by MCA 28A32 AT 0537168
AU 660,927
BE 0537168
CA 2079601
XX 0000000
XX 0000000
DK 0537168
EP 0537168
ES 0537168
FI 000000
XX 0537168
GB 0537168
GR 0537168
IT 0537168
XX 000000/00
XX 92/702530
LU 0537168
NL 0537168
17
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
Title Country Patent # Allowed App # Filed App #
SE 0537168
WO US91/02459
Antigen recognized by MCA 16.88 US 5,338,832
AT E137674
AU 618,209
BE 0328578
CA 571,017
CH 0328578
DE P3855290.9
DK 1025/89
EP 0328578
FR 0328578
GB 0328578
HU 4187/88
IE 2034/88
IL 86,958
IT 0328578
JP 505983/89
LU 0328578
NL 0328578
NZ 225,280
SE 0328578
WO US88/02245
ZA 88/4777
Keyhole limpet hemocyanin composition US 5,407,912 08/343808
with enhanced immunogenic activity
AU 60519/94
CA 2121296
EP 94200997.8
18
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
Title Country Patent # Allowed App # Filed App #
FI 941725
ID P-940578
XX 000000/00
XX 94/8063
ZA 94/2510
Tumor associated epitope US 08/478591
CTAA 81AV78, the antigen recognized US 08/150036
by human monoclonal antibody 81AV78
AU 20085/92
CA 2102422
EP 92912470.9
FI 934,963
XX 000000/00
XX 93/703413
WO US92/04108
Others
Leukoregulin, an antitumor lymphokine US 4,849,506
and its therapeutic uses 5,082,657
AT ?48617
AU 592,529
641,386
BE 0179127
CA 478,987
CH 0179127
DE P3574710.2
DK 170,781
170,423
EP 0179127
FI 85,867
FR 0179127
OB 0179127
19
SCHEDULE A
PATENTS AND PATENT APPLICATIONS
Title Country Patent # Allowed App # Filed App #
IT 0179127
JP 501862/85
LU 0179127 300409/93
NL 0179127
NO 170,423
SE 0179127
WO US85/00626
Urethral catheter and US 5,120,316
catheterization process
Immunoreactive peptides of apo(a) US 08/266407
08/456840
08/457449
08/172461
AU 81.606/94
CA 2138605
EP 94203653.4
FI 945976
ID P-942209
XX 000000/00
XX 94/358098
ZA 94/10145
An alignment system to overlay US 5,299,253
abdominal computer aided tomography
and magnetic resonance anatomy with
single photon emission tomography
20
Schedule B
Intellectual Property Security Agreement
Trademarks
OncoSpect(TM)
Oncovax(TM)
Onconostika(TM)
Oncoscan(TM)
Oncoselect(TM)
Apo-Tek Lp(a)*
Apo-Tek Apo E*
KLH Immune Activator*
* Final name and registration to be completed
